Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn's Disease: A Belgian Multicentric Cohort Study.

Dahham AlsoudJoão SabinoDenis FranchimontAnneline CremerJulie BusschaertFrançois D'HeygerePeter BossuytAnne VijvermanSéverine VermeireMarc Ferrante

Published in: Inflammatory bowel diseases (2024)

In this real-world cohort of multirefractory CD patients, risankizumab was effective in inducing both clinical remission and endoscopic response. Risankizumab was well tolerated with no safety issues.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
early onset
ultrasound guided
rheumatoid arthritis
ulcerative colitis
patient reported